NDA 211210 · Tersera
Qmiiz Odt
Meloxicam · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Apr 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Oct 19, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
142
48 Phase 3, 10 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 19, 2018 Original approval · Type 3 - New Dosage Form LabelMedication GuideLetter
2 products under this application
- QMIIZ ODT · MELOXICAM 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORALLY DISINTEGRATING, ORAL · Discontinued
- QMIIZ ODT · MELOXICAM 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORALLY DISINTEGRATING, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Meloxicam" as an intervention, any sponsor and status, largest first.
- The Standard Care Versus Celecoxib Outcome TrialPivotal-lookingCompleted
University of DundeeAcademic, hospital or other
NCT00447759 · 7,297 participants · Start Jun 2007 · Primary completion Aug 2015
Drug: Celecoxib; Diclofenac · For: Osteoarthritis; Rheumatoid Arthritis
Sites: Odense, Denmark; Zeist, Netherlands; Aberdeen, United Kingdom · 10 sites in all
- Maximizing Outcomes in Treating Acute MigrainePivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT03896009 · 1,594 participants · Start Mar 4, 2019 · Primary completion Dec 10, 2019
Drug: AXS-07 (MoSEIC meloxicam and rizatriptan); Meloxicam and 2 more · For: Migraine
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 85 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT02183064 · 1,309 participants · Start Oct 1998 · Primary completion Nov 2000
Drug: Meloxicam; NSAID · For: Osteoarthritis
- A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid ArthritisPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00042068 · 1,000 participants · Start Jun 2002
Drug: Meloxicam · For: Arthritis, Rheumatoid
Sites: Huntsville, Alabama; Montgomery, Alabama; Anchorage, Alaska · 153 sites in all
- Evaluation of N1539 Following Major SurgeryPivotal-lookingCompleted
Baudax BioIndustry
NCT02720692 · 722 participants · Start Mar 2016 · Primary completion Mar 2017
Drug: N1539; Intravenous Placebo · For: Pain, Post-operative
Sites: Florence, Alabama; Montgomery, Alabama; Sheffield, Alabama · 32 sites in all
- Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)Pivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT04068051 · 706 participants · Start Jul 6, 2019 · Primary completion Sep 22, 2020
Drug: AXS-07 · For: Migraine
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 51 sites in all
- Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or HipPivotal-lookingCompleted
Iroko Pharmaceuticals, LLCIndustry
NCT01801735 · 600 participants · Start Mar 2013 · Primary completion Jun 2014
Drug: Meloxicam Test Capsules · For: Osteoarthritis
Sites: Birmingham, Alabama; Phoenix, Arizona; Carmichael, California · 40 sites in all
- Opioid-Free Orthopaedic SurgeryPivotal-lookingCompleted
OrthoCarolina Research Institute, Inc.Academic, hospital or other
NCT04176783 · 511 participants · Start Mar 26, 2018 · Primary completion Jul 21, 2021
Drug: Opioids; Opioid-Free · For: Pain Management
Sites: Charlotte, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Nonsteroidal Anti-Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis.
Tawfik AG, Gomez-Lumbreras A, Del Fiol G, et al. · Clin Pharmacol Ther 2026 · Systematic Review, Meta-Analysis
- Bioequivalence of Meloxicam Nanocrystal Injection in Healthy Chinese Volunteers.
Hu S, Liu X, Wan Q, et al. · Clin Pharmacol Drug Dev 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy of tramadol for postoperative pain management in dogs: systematic review and meta-analysis.
Donati PA, Tarragona L, Franco JVA, et al. · Vet Anaesth Analg 2021 · Meta-Analysis, Systematic Review
- Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project).
Castellsague J, Riera-Guardia N, Calingaert B, et al. · Drug Saf 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Early perioperative versus postoperative meloxicam for pain control in patients undergoing orthopedic surgery: a systematic review and Meta-analysis of randomized controlled trials.
Mahmoud A, Abuelazm M, Ashraf Salah Ahmed A, et al. · Curr Med Res Opin 2023 · Meta-Analysis, Systematic Review
- Potential candidate for oral pericoital contraception: evaluating ulipristal acetate plus cyclo-oxygenase-2 inhibitor for ovulation disruption.
Cahill EP, Lerma K, Shaw KA, et al. · BMJ Sex Reprod Health 2022 · Clinical Trial, Phase I
Sponsor: Tersera
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.